Sanofi wins EU green light for new MS drug Lemtrada
LONDON, June 28
LONDON, June 28 (Reuters) - French firm Sanofi has won a European green light for its new multiple sclerosis medicine Lemtrada, after a quarter-century drug development saga.
Lemtrada, also known as alemtuzumab, has been studied in multiple sclerosis (MS) since the early 1990s but its progress to market as a treatment for the disease has been halting and the drug has changed hands many times.
The European Medicines Agency said on Friday it was recommending Lemtrada for relapsing-remitting MS. EMA decisions are usually endorsed by the European Commission within a couple of months. (Reporting by Rosalba O'Brien and Caroline Copley)
- Ukraine accuses Russia of "undisguised aggression" as rebels advance |
- Disruptive Hong Kong protests loom after China rules out democracy |
- Syrian army, rebels fight on Golan where peacekeepers held |
- NATO to create new 'spearhead' force to respond to crises
- Investors look past Ukraine, focus on ECB